Valuation: Travere Therapeutics, Inc.

Market Cap 6.1B 5.32B 5.02B 4.56B 8.55B 586B 8.58B 60.19B 23.23B 298B 22.92B 22.41B 958B P/E 2026 *
-536x
P/E 2027 * 22.8x
Enterprise Value 6.14B 5.36B 5.06B 4.59B 8.61B 590B 8.64B 60.6B 23.38B 300B 23.08B 22.57B 964B EV / Sales 2026 *
8.48x
EV / Sales 2027 * 5.45x
Free-Float
95.23%
Yield 2026 *
-
Yield 2027 * -
1 day-3.06%
1 week-7.04%
Current month-5.31%
1 month-1.21%
3 months+15.92%
6 months+126.08%
Current year+64.25%
1 week 61.4
Extreme 61.4
67.88
1 month 61.4
Extreme 61.4
68.73
Current year 22.59
Extreme 22.59
68.73
1 year 22.06
Extreme 22.055
68.73
3 years 5.12
Extreme 5.12
68.73
5 years 5.12
Extreme 5.12
68.73
10 years 5.12
Extreme 5.12
68.73
Manager TitleAgeSince
Chief Executive Officer 53 2019-01-03
Director of Finance/CFO 42 2022-08-30
Chief Tech/Sci/R&D Officer 51 2022-01-03
Director TitleAgeSince
Chairman 75 2016-05-17
Chairman 59 2015-06-07
Director/Board Member 59 2015-03-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/10/26 Exercice

Director

60,000 0.0645%
9/2/26 Sell

Chief Financial Officer

-642 0.0007%
8/18/26 Exercice

Chairman

15,000 0.0161%
Change 5-day change 1-year change 3-year change Capi.($)
-3.06%-7.04%+165.37%+358.44% 6.1B
-0.31%+3.56%+46.40%+100.50% 70.89B
+0.39%+1.82%+38.93%+77.73% 62.32B
-3.21%-5.72%-17.12%+350.96% 27.07B
-2.64%-0.35%-2.13%-15.04% 24.78B
+0.71%+8.50%+27.76%-15.29% 20.59B
-1.26%-10.61%+170.72%+290.48% 15.52B
-0.22%+1.62%+44.31%+167.58% 14.49B
+0.73%+5.00%-1.33%+854.55% 14.14B
-0.54%-0.30%+27.33%+202.19% 12.35B
Average -0.94%+1.10%+50.03%+237.21% 26.83B
Weighted average by Cap. -0.65%+1.26%+38.74%+165.82%

Financials

2026 *2027 *
Net sales 725M 632M 597M 542M 1.01B 69.52B 1.02B 7.15B 2.76B 35.35B 2.72B 2.66B 114B 1.08B 944M 891M 809M 1.52B 104B 1.52B 10.68B 4.12B 52.81B 4.07B 3.98B 170B
Net income -3.23M -2.82M -2.66M -2.42M -4.53M -310M -4.54M -31.86M -12.29M -158M -12.14M -11.87M -507M 243M 212M 200M 182M 340M 23.3B 342M 2.39B 924M 11.85B 912M 892M 38.12B
Net Debt 41.4M 36.1M 34.09M 30.95M 58M 3.97B 58.24M 408M 158M 2.02B 156M 152M 6.5B -208M -182M -172M -156M -292M -20.01B -293M -2.06B -794M -10.17B -783M -766M -32.73B
Logo Travere Therapeutics, Inc.
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Employees
497
Date Price Change Volume
26-09-18 US$62.76 -3.06% 2,235,840
26-09-17 US$64.74 +1.98% 1,384,698
26-09-16 US$63.48 +1.55% 2,221,345
26-09-15 US$62.51 -4.99% 2,097,801
26-09-14 US$65.79 -0.57% 924,717
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
62.76USD
Average target price
74.21USD
Spread / Average Target
+18.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TVTX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!